Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-13
2008-05-13
Tate, Christopher (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S320100, C435S325000
Reexamination Certificate
active
07371727
ABSTRACT:
The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
REFERENCES:
patent: 5140102 (1992-08-01), Currie
patent: 5395490 (1995-03-01), Hoff et al.
patent: 5489670 (1996-02-01), Currie et al.
patent: 5969097 (1999-10-01), Wiegand et al.
patent: 6060037 (2000-05-01), Waldman
patent: 2003/0073628 (2003-04-01), Shailubhai et al.
patent: 2003/0232013 (2003-12-01), Siechman et al.
patent: 2004/0121961 (2004-06-01), Masferrer
patent: 2004/0152868 (2004-08-01), Larsen et al.
patent: 2004/0258687 (2004-12-01), Waldman et al.
patent: 2004/0266989 (2004-12-01), Currie et al.
patent: 2005/0032684 (2005-02-01), Cetin et al.
patent: 1012188 (2000-06-01), None
patent: WO 99/14239 (1999-03-01), None
patent: WO 01/25266 (2001-04-01), None
patent: WO 02/062369 (2002-08-01), None
patent: WO 02/078683 (2002-10-01), None
patent: WO 02/079235 (2002-10-01), None
patent: WO 02/098912 (2002-12-01), None
patent: WO 03/072125 (2003-09-01), None
patent: WO 2004/071436 (2004-08-01), None
Amarante et al., “The κ-opioid agonist(±)-bremazocine elicits peripheral antinociception by activation of the L-arginine
itric oxide/cyclic GMP pathway”European Journal of Pharmacology, vol. 454: pp. 19-23 (2002).
Arita et al., “Purification and characterization of a heat-stable enterotoxin of Vibrio mimicus”FEMS Microbiology Letters, vol. 79/1: p. 105-110 (1991).
Chan et al., “Amino Acid Sequence of Heat-stable Enterotoxin Produced byEscherichia coliPathogenic for Man”The Journal of Biological Chemistry, vol. 256, No. 15: pp. 7744-7746 (1981).
Forte et al., “Lymphoguanylin: Cloning and Characterization of a Unique Member of the Guanylin Peptide Family”Endocrinology, vol. 140, No. 4: pp. 1800-1806 (1999).
Giannela, “Escherichia coliheat-stable enterotoxins, guanylins, and their receptors: What are they and what do they do?”The Journal of Laboratory and Clinical Medicine, vol. 125, No. 2: pp. 173-181 (1995).
Gualillo et al., “Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action”FEBS Letters, vol. 552: pp. 105-109 (2003).
Guarino et al., “Citrobacter freundii Produces an 18-Amino-Acid Heat-Stable Enterotoxin Identical to the 18-Amino-AcidEscherichia coliHeat-Stable Enterotoxin (ST Ia)”Infection and Immunity, vol. 57, No. 2: pp. 649-652 (1989).
Huang et al., “Nucleotide sequence of a gene encoding the novel Yersinia enterocolitica heat-stable enterotoxin that includes a pro-region-like sequence in its mature toxin molecule”Microbial Pathogenesis, vol. 22: pp. 89-97 (1997).
Jain et al., “Sildenfil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway”Brain Research, vol. 909: pp. 170-178 (2001).
Kim et al., “Changes in ghrelin and ghrelin receptor expression according to feeding status”NeuroReport, vol. 14, No. 10: pp. 1317-1320 (2003).
Lazaro-Ibanez et al., “Participation of the nitric oxide-cyclic GMP-ATP-sensitive K+channel pathway in the antinociceptive action of ketorolac”European Journal of Pharmacology, vol. 426: pp. 39-44 (2001).
Moseley et al., “Isolation and Nucleotide Sequence Determination of a Gene Encoding a Heat-Stable Enterotoxin ofEscherichia coli” Infection and Immunity, vol. 39, No. 3: pp. 1167-1174 (1983).
Nzegwu et al., “Luminal capsaicin inhibits fluid secretion induced by exterotoxinE. coliSTa, but not by carbachol, in vivo in rat small and large intestines”Experimental Physiology, vol. 81, No. 2: pp. 313-315 (1996).
Rolfe et al., “EnterotoxinEscherichia coliSTa activates a nitric oxide-dependent myenteric plexus secretory reflex in the rat ileum”The Journal of Physiology, vol. 475, No. 3; pp. 531-537 (1994).
Rolfe et al., “Vagotomy inhibits the jejunal fluid secretion activated by luminal ilealEscherichia coliSTa in the rat in vivo”GUT, vol. 44: pp. 615-619 (1999).
Shailubhai, “Therapeutic applications of guanylate cyclase-C receptor agonists”Drug Discover&Development, vol. 5 No. 2: pp. 261-268 (2002).
So et al., “Nucleotide Sequence of the Bacterial Transposon Tn1681 Encoding a Heat-Stable (ST) Toxin and Its Identification in EnterotoxigenicEscherichia coliStrains”Proceedings of the National Academy of Sciences of the U.S.A., vol. 77, No. 7 [Part 2: Biological Sciences]: pp. 4011-4015 (1980).
Soares, et al., “Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K+channels in the RAT PGE2-induced hyperalgesic paw”British Journal of Pharmacology, vol. 134: pp. 127-131 (2001).
Takao et al., “Amino acid sequence of heat-stable enterotoxin produced byVibrio choleranon-01”FEBS), vol. 193, No. 2: pp. 250-254 (1985).
Takao et al., “Isolation, primary structure and synthesis of heat-stable enterotoxin produced byYersinia enterocolitica” European Journal of Biochemistry, vol. 152, No. 1: pp. 199-206 (1985).
Vaandrager et al., “Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C”Molecular and Cellular Biochemistry, vol. 230, Nos. 1&2: pp. 73-83 (2002).
GenBank Accession No. QHECIB; GI:69638; Aimoto et al., Jun. 18, 1999.
GenBank Accession No. P01559; GI:123711; So et al., Oct. 25, 2004.
GenBank Accession No. AAA24653:GI:147878; Sekizaki et al., Apr. 26, 1993.
GenBank Accession No. P01560; GI:123707; Chan et al., Jun. 15, 2004.
GenBank Accession No. AAA27561; GI:295439; Ogawa et al., Jun. 12, 1993.
GenBank Accession No. P04429; GI:123712; Ogawa et al., Jun. 15, 2004.
GenBank Accession No. S34671; GI:421286; Rossolini et al., Apr. 12, 1995.
GenBank Accession No. CAA52209; GI:395161; Guglielmetti et al., Jul. 27, 2995.
GenBank Accession No. A54534; GI:628844; Arita et al., May 3, 1996.
GenBank Accession No. AAL02159; GI:15592919; Teixeira et al., Sep. 13, 2001.
GenBank Accession No. AAA18472; GI:487395; Mikulskis et al., May 26, 1994.
GenBank Accession No. S25659, GI:282047; Takao et al., Oct. 15, 1999.
GenBank Accession No. P74977: GI:3913874; Ramamurthy et al., Jun. 15, 2004.
GenBank Accession No. BAA23656; GI:2662339; Huang et al., Feb. 13, 1999.
GenBank Accession No. P31518; GI:399947; Ibrahim et al., Mar. 15, 2004.
GenBank Accession No. P07965; GI:3915589; Stieglitz et al., Jun. 15, 2004.
Camilleri, “Management of the Irritable Bowel Syndrome” Gastroenterology 120:652-668, 2001.
Drossman, D.A., “The functional gastrointesinal disorders and the Rome II process” Gut 45:Supp. II:111-113, 1999.
Drossman, D.A., “Psychosocial aspects of the functional gastrointestinal disorders” Gut 45:Supp. II:1125-1130, 1999.
Drossman et al., “U.S. Householder Survey of Functional Gastrointestinal Disorders” Digestive Diseases and Sciences 38(9):1569-1580, 1993.
Ringel, et al., “Irritable Bowel Syndrom” Annu. Rev. Med. 52:319-38, 2001.
Santos-Neto, et al., “Guanylin and its Lysine-Containing Analogue in the Isolated Perfused Rat Kidney” Pharmacol. & Toxicol. 92:114-120, 2003.
Talley, et al., “Irritable Bowel Syndrome in a Community: Sympton Subgroups, Risk..ȁ
Currie Mark G.
Fretzen Angelika
Mahajan-Miklos Shalina
Milne G. Todd
Norman Thea
Fish & Richardson P.C.
Microbia, Inc.
Tate Christopher
Teller Roy
LandOfFree
Methods and compositions for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2802965